Press Releases
November 22, 2023 | Incendia Therapeutics to Present at 35th Annual Piper Sandler Healthcare Conference
November 13, 2023 | Incendia Therapeutics Appoints Wendye Robbins, M.D., as Chief Executive Officer and Doses First Patient in Phase 1b Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor
October 31, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting
October 16, 2023 | Incendia Therapeutics Announces Upcoming Presentations at the European Society for Medical Oncology Congress 2023
June 22, 2023 | Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of PRTH-101 Inhibiting DDR1 in Immune Excluded Tumors
June 12, 2023 | Parthenon Therapeutics Announces Publication in Journal for ImmunoTherapy of Cancer on the Role of Immune Exclusion in Cancer
April 25, 2023 | Parthenon Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor for the Treatment of Immune-Excluded Solid Tumors
April 17, 2023 | Parthenon Therapeutics Announces Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 on Prevalence of Immune Exclusion in Solid Tumors to Support Phase 1 Clinical Trial of PRTH-101
December 15, 2022 | Parthenon Therapeutics Appoints Joseph Paul Eder, MD, as Chief Medical Officer
November 16, 2022 | Parthenon Therapeutics Showcases New Precision Oncology Technology Designed to Breakdown Barriers in Immune-excluded Tumors
November 10, 2022 | Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
